68 results about "Biliary ducts" patented technology

The invention belongs to the technical field of organoid culture, and particularly relates to a co-differentiated vascularized liver organoid and a construction method thereof. Aiming at the problems that the existing liver organ vascularization mostly adopts a co-culture mode, the operation process is complicated, the cell source heterogeneity is relatively high, the randomness is strong, the uniformity is poor and the like, the invention provides the construction method of the co-differentiated vascularized liver organ. The preparation method comprises the following steps: sequentially inducing and culturing directional endoderm cells, posterior preintestinal cells and hepatic endoderm cells, adding an S1 culture medium containing VEGF to induce and culture for 1-3 days, then adding an S2 culture medium containing VEGF, BMP4 and FGF2 to induce and culture for 3-5 days, and then adding an S3 culture medium containing VEGF to induce and culture for 14-20 days to obtain the co-differentiated vascularized liver organ. According to the method disclosed by the invention, the operation process is simplified, the experiment efficiency is improved, the liver organ which is rich in blood vessel network, high in maturity and of a blood vessel-bile duct structure is obtained, and a foundation is laid for large-scale production and clinical application.

The invention provides an intraoperative real-time navigation system based on digital twinning, and relates to the technical field of digital twinning, and the system comprises a data collection module which is used for obtaining the three-dimensional form data of a liver and a biliary tract through an intraoperative ultrasonic imaging device, and collecting the elastic modulus distribution parameters of liver parenchyma and a bile duct wall; the construction registration module is used for constructing a real-time digital twin in the liver and gall area based on the three-dimensional form data and the elastic modulus distribution parameters, and carrying out multi-mode non-rigid registration on the digital twin and the liver surface topography and the vascular structure which are subjected to optical coherence tomography in the operation; therefore, a dynamic space mapping relation between the organ structure and the image data is established. According to the method, real-time navigation in the operation is realized through digital twinning, the obstacle avoidance path is updated, and the safety and efficiency in the operation are improved.

Hydrodynamic injection of nucleic acid or protein for in vivo gene therapy to biliary duct, liver, pancreas, and kidney of a subject.

The invention discloses application of miRNA in diagnosis, prediction and treatment of bile duct cancer, and relates to the technical field of biological pharmacy. Specifically, the invention provides a reagent for promoting miR-26 expression or exerting physiological functions, and / or a simulation compound with the same physiological functions as miR-26, and an application method of the reagent in preparation of drugs for treating bile duct cancer, and provides a possibility for treating bile duct cancer and guiding research, development and screening of related drugs. The invention also provides a product for diagnosing and / or predicting the biliary duct cancer of a subject, and the expression level of miR-26 can be detected by using the product, so that the risk of the subject suffering from the biliary duct cancer can be predicted, and the severity of the biliary duct cancer can be diagnosed; and a possibility is provided for diagnosing the bile duct cancer.

The utility model relates to the technical field of medical instruments, and discloses a sticking device for fixing a nasobiliary duct, which comprises the nasobiliary duct, a limiting component comprises an elliptical block A and an elliptical strip arranged at the middle end of one side of the elliptical block A, and a spiral groove is formed in the outer surface of the elliptical strip. The restraining component comprises an oval block B and an oval inserting strip installed at the middle end of one side of the oval block B. The nasobiliary duct is wound along the outer surface of the oval strip and located in the spiral groove, the positioning strip and the oval inserting strip are inserted into the positioning inserting groove and the oval hollow long strip correspondingly, and the outer wall of the cam strip makes contact with the outer surface of the nasobiliary duct. The bolt is in threaded connection with the interior of the threaded circular groove, the position of the rotating rod is fixed, and the nasobiliary duct is protected through the limiting component and the restraining component, so that the body of the patient is prevented from being pressed on the nasobiliary duct.

The present invention relates to an equipment for magnetic recanalization of benign biliary strictures. The equipment (100) includes a wire-guided magnet pusher tube (102a), atleast one magnet (110), and a magnet retrieval tube (102b). The equipment (100) works in conjunction with a visualization system to guide placement of the magnet (110) at the target site for recanalization of the biliary stricture. The magnet (110), may be deployed at opposing ends of a biliary stricture to create a controlled recanalization channel via magnetic attraction. The deployment process can be performed using endoscopic retrograde cholangiopancreatography (ERCP), percutaneous transhepatic biliary drainage (PTBD), or a combination of both. Magnets may be retrieved following recanalization using biopsy forceps or allowed to pass naturally through the digestive tract, avoiding permanent implantation.

The invention relates to the technical field of medical instruments, and discloses a visual biliary tract rotary cutting biopsy expansion system assembly which comprises a conical sleeve, a visual mechanism is fixedly connected to the interior of the conical sleeve, a holding mechanism is installed on the left side of the visual mechanism, a rotary cutting mechanism is installed at the left end of the holding mechanism, and the visual mechanism comprises a cable. The exterior of the cable is fixedly connected to the interior of the conical sleeve, the top end of the cable is fixedly connected with a golden finger, the left end of the conical sleeve is fixedly connected with a protection assembly, the left end of the protection assembly is fixedly connected with a Luer lock cap, and the interior of the protection assembly is fixedly connected with an insertion pipe; a light source is fixedly connected into the protection assembly. The inside of the biliary tract is uniformly and sufficiently illuminated through the light source, a clear observation view is provided for a doctor, the doctor can accurately judge the illness state, and the situation that the positive rate of hepatopathic bile duct malignant stenosis biopsy is not high is reduced.

The application relates to the field of metal nanopowder or plasma spraying, and particularly discloses a biliary stent prepared by combining metal nanopowder with a plasma spraying process. The ZrNbFeLa coating prepared by the plasma spraying process has good corrosion resistance, but the hemolysis rate is poor. Further, a proper amount of metal Ti is injected into the ZrNbFeLa coating, so that the biocompatibility of the ZrNbFeLa coating can be significantly improved, the corrosion resistance is not greatly affected, and the ZrNbFeLa coating can meet the use requirements of medical materials such as the biliary stent. It should be noted that the ion injection amount of the metal Ti needs to be controlled within 2.8*10 5 ions / cm 2 -1.2*10 12 ions / cm 2 , otherwise, too much titanium will cause the corrosion resistance of the ZrNbFeLa coating to sharply decrease.

The invention relates to the technical field of nasobiliary ducts, and discloses a nasobiliary duct in-vitro fixing device which is characterized in that a first arc-shaped groove is formed in the top of a connecting block, a second arc-shaped groove is formed in the bottom of the connecting block, a first adjusting mechanism is arranged in the connecting block, and a second adjusting mechanism is arranged on the front face of the connecting block; the first adjusting mechanism comprises sliding assemblies and limiting assemblies, the sliding assemblies are arranged on the left side and the right side in the connecting block, the limiting assemblies are arranged on the left side and the right side of the connecting block, the second adjusting mechanism comprises a position changing assembly and a fixing assembly, and the position changing assembly is arranged on the front face of the connecting block. The fixing assembly is arranged on the front face of the transposition assembly. A fixing block is moved through a second adjusting mechanism, so that the nasobiliary duct moves left and right, the nasobiliary duct can be adjusted left and right according to the nostril of a patient, after the fixing block is adjusted, the nasobiliary duct is inserted into a fourth connecting hole, and after insertion, the nasobiliary duct is fixed through the elastic force of a third spring.

The present invention relates to a pharmaceutical composition comprising a compound selected from the group consisting of elafibranor, 2-[2,6-dimethyl-4-[3-[4-(methylthio)phenyl]-3-oxo-propyl]phenoxy]-2-methylpropanoic acid (GFT1007), and a pharmaceutically acceptable salt of elafibranor or GFT1007, for use in a method for reducing fatigue in subject having primary biliary cholangitis (PBC). The pharmaceutical composition of the invention provides a significative reduction of the PROMIS Fatigue T-score (PROMIS Short Form - Fatigue 7a questionnaire (V1.0)) from baseline in a subject having PBC.

The invention relates to the technical field of tumor immunotherapy, in particular to an HLA restrictive neoantigen polypeptide based on malignant ascites tumor cells and application of the HLA restrictive neoantigen polypeptide. The invention provides cholangiocarcinoma neoantigen polypeptide. The amino acid sequence of the neoantigen polypeptide is shown as SEQ ID NO.1, 2 or 3. The tumor neoantigen polypeptide is separated and screened from malignant ascites of a biliary duct cancer patient, has high affinity with HLA molecules, can stimulate generation of tumor specific T cells, further generates immune response of targeted tumor cells, can be used as a target spot for clinical treatment or diagnosis of tumors, and has good application prospects. Good application prospects are realized in tumor immunotherapy.

To provide a device for an endoscope improved in insertability when inserting a treatment instrument into a biliopancreatic duct.SOLUTION: An endoscopic device includes a sheath extending in a longitudinal direction, a treatment tool opening portion communicating with a treatment tool lumen through which the sheath is inserted in the longitudinal direction and configured to allow a treatment tool inserted through the treatment tool lumen to protrude and retract to and from a distal end side of the sheath in the longitudinal direction, and a suction opening portion communicating with a suction lumen through which the sheath is inserted in the longitudinal direction.SELECTED DRAWING: Figure 3

The utility model relates to the technical field of medical instruments, in particular to a nasobiliary drainage assembly which comprises a nasobiliary and a drainage component, and the drainage component comprises a drainage bag, a connecting tube, an external threaded tube, an internal threaded tube, a cleaning tube, a control mechanism, a first liquid inlet hopper and a second liquid inlet hopper. The nasobiliary duct is inserted into a patient and used for biliary drainage of the patient, the connecting tube and the nasobiliary duct are connected through the outer threaded tube and the inner threaded tube, threaded connection installation is adopted, sealing performance is achieved, disassembly and replacement can be convenient, the nasobiliary duct is prevented from being taken out when the drainage bag is replaced, the number of times of inserting the drainage bag into the body of the patient is reduced, and pain of the patient is relieved. When the communicating pipe is blocked, the communicating pipe and the nasobiliary duct are sealed through the control mechanism, blockages in the communicating pipe are washed out by injecting water into the cleaning pipe, so that the smoothness of the connecting pipe is guaranteed, and if the connecting pipe and the nasobiliary duct are difficult to clean, the connecting pipe and the nasobiliary duct can be cleaned or replaced after being detached.

The present invention provides a bifunctional molecular compound that induces MMP-7 protein degradation or a pharmaceutically acceptable salt, hydrate or prodrug thereof, wherein the structure of the compound is shown in Formula I or II: #imgabs0#Formula I; #imgabs1#Formula II. The present invention also provides a method for preparing the above-mentioned compound and a pharmaceutical composition. In addition, the present invention also provides the use of the above-mentioned compound, its pharmaceutically acceptable salt, hydrate, prodrug, or pharmaceutical composition in the preparation of a drug for treating biliary atresia. The present invention is supported by PROTAC technology and uses MMP-7 inhibitors as raw materials to synthesize bifunctional molecular compounds with different linker lengths that induce MMP-7 protein degradation; by using the bifunctional molecular compound after biliary atresia surgery, effective degradation of MMP-7 protein can be achieved, inflammatory bile duct damage and liver fibrosis progression can be inhibited, and a new treatment strategy for biliary atresia can be provided.

The invention belongs to the technical field of biological medicines, and particularly relates to application of PF-06260933 in preparation of a medicine for treating biliary atresia. The invention provides an application of an HGK inhibitor PF-06260933 in preparation of a medicine for treating biliary atresia. A BA organ and biliary duct ligation (BDL) induced mouse model is constructed, PF-06260933 is adopted to inhibit pro-inflammatory and pro-fibrosis related signal channels of biliary duct epithelial cells, and the improvement effect of PF-06260933 on biliary duct atresia pathological phenotypes is observed. Results show that the PF-06260933 treatment not only can significantly improve inflammatory fibrosis phenotypes of BA organs, but also can significantly improve mouse liver functions, relieve liver inflammation and fibrosis, and effectively reverse pathogenic activation phenotypes of bile duct epithelial cells. Compared with the traditional niberous surgery or non-specific immunosuppression therapy, the method has the advantages of remarkable progress and huge clinical application potential.

A tissue lumen stent is provided with a body having an elongated tubular configuration and a foreshortened configuration. In the foreshortened configuration, downstream and upstream ends of the body expand radially into downstream and upstream flange structures, leaving a generally cylindrical saddle region therebetween. In some embodiments, the flange structures are non-symmetrical with respect to one another. Systems and methods of using the stents are also disclosed.

The invention relates to the technical field of medical instruments, in particular to an ERCP novel bile duct stent and a preparation method thereof.The bile duct stent prepared through the preparation method has certain antibacterial ability by using an AMP-Chol12 peptide chain with the antibacterial ability, the bacterial membrane structure is destroyed through the electric charge effect, bacterial death is caused, and the bile duct stent has a certain antibacterial ability. Therefore, the bacterial infection risk is reduced. The physical antibacterial mechanism does not depend on chemical release, so that the antibacterial property is lasting, silver ions and antibiotics are not contained, bacterial drug resistance is not caused, meanwhile, good biocompatibility is achieved, the lubricating property can be improved, friction and damage are reduced, and bile sludge deposition is reduced.

The invention discloses application of an NLRP3 inhibitor in preparation of a medicine for treating biliary atresia. The NLRP3 inhibitor can selectively inhibit inflammasome NLRP3 generated due to activation of an abnormal universal apoptosis pathway, further inhibits a proinflammatory factor product IL-1beta, effectively relieves formation of biliary duct atresia of BA mice, reduces the jaundice rate, and improves the body weight and the survival rate.

The invention discloses a preparation method and application of exosome-loaded Cas13d-RNP, and belongs to the technical field of biliary atresia research. The method comprises the following steps: extracting exosomes: culturing human bile duct cells H69 in a DMEM / F12 culture medium until the cell density reaches 90%, collecting supernatant of the culture medium, and extracting the exosomes by an ultracentrifugation method; cas13d-RNP loading: the Cas13d protein and crRNA are mixed for 15 minutes at the room temperature, Cas13d-RNP is obtained, the exosome and the Cas13d-RNP are mixed, and the Cas13d-RNP is loaded into the exosome in a circulating freezing and thawing mode. According to the invention, Cas13d-RNP is accurately delivered through the exosome vector, specific targeting is carried out on bile duct cell CTGF mRNA, and expression of fibrosis-related factors in bile duct cells is significantly reduced. Compared with traditional medicine treatment, bile duct reaction and fibrosis processes can be more effectively inhibited. As a natural vector, the exosome has the advantages of low immunogenicity and high delivery efficiency, and immunoreactions possibly caused by a traditional virus vector are reduced.

Medical devices and method for making and using the same are disclosed. An example medical device may include implantable medical device for use along the biliary and / or pancreatic tract. The implantable medical device may include a tubular member having a first end configured to be disposed within the duodenum of a patient and a second end configured to be disposed adjacent to a pancreatic duct and / or bile duct. The tubular member may have a body including one or more wire filaments that are woven together. The tubular member may also have an outer surface with a longitudinal channel formed therein.

This invention provides apparatus, methods, and kits that allow for simplified stent placement and retention in biological tubes other than blood vessels, particularly in antegrade biliary stent placement. The apparatus and methods advantageously allow for shorter imaging and stent placement times and significantly improve stent tolerance and / or retention in the tube. In a further advantageous aspect, the envisioned stent forms a complex fluid path to facilitate drainage of the tube. Furthermore, the apparatus and methods proposed herein reduce or even completely eliminate partial contraction of the peritoneal space during imaging and stent placement, and thus prevent operator exposure to exhaust gases carrying harmful agents.

The invention belongs to the technical field of biological medicine, and particularly relates to a biliary atresia differential diagnosis and prognosis marker and application thereof. The invention provides the application of the KRT17 expression level as a biliary atresia differential diagnosis and prognostic marker for the first time. KRT17 as a single marker has a relatively high diagnostic value (AUC = 0.880) for BA, the efficiency of KRT17 is superior to all conventional clinical liver function indexes, and when KRT17 is combined with alanine aminotransferase for use, the diagnostic accuracy can be further improved to AUC = 0.904, the KRT17 and CX3CL1 are optimally combined, and the AUC value is as high as 0.938. According to the technology, KRT17 is used as a novel biliary atresia differential diagnosis marker, the defects of an existing differential diagnosis system can be made up to a certain degree, the KRT17 is specifically and highly expressed in biliary atresia liver bile duct epithelial cells, normal control and disease control are not expressed, and therefore more accurate differential diagnosis can be provided clinically.

The invention belongs to the technical field of anti-tumor pharmaceutical preparations, and particularly relates to a pharmaceutical preparation for inhibiting biliary duct cancer kinesiology and a preparation method thereof.The pharmaceutical preparation is prepared from, by weight, 10 parts of a UBE2M inhibitor, 80-100 parts of PLGA, 15-20 parts of DSPE-PEG2000-T7, 5 parts of a stabilizer and 8 parts of a penetrant, the UBE2M inhibitor with high binding force to UBE2M is obtained through virtual screening of a computer, and the UBE2M inhibitor with high binding force to the biliary duct cancer is used for inhibiting biliary duct cancer kinesiology. The UBE2M inhibitor has good pharmacological activity, can obviously inhibit the activity of UBE2M through inhibition so as to influence the PHB2 protein level and the quasi-kinesization process and achieve the anti-bile duct cancer effect, meanwhile, the UBE2M inhibitor is prepared into a nano preparation through a modification material with hydrophilic and hydrophobic and targeting characteristics, the leakage situation of the medicine in the in-vivo circulation process can be effectively reduced, and the anti-bile duct cancer effect is achieved. The accumulation at the nidus part of the bile duct cancer is improved.

A system for accessing a biliary duct includes an access cannula (102) and a needle (104). The cannula (102) extends longitudinally from a proximal end to a distal end and includes a channel extending therethrough. A distal portion of the cannula includes an echogenic pattern (108) defined via echogenic segments, each of which are separated from one another via a space so that the echogenic pattern is configured to produce alternating bright and dark regions, when visualized under ultrasound guidance. The needle (104) extends longitudinally from a proximal end to a distal end, and sized, shaped, and configured to be received within the channel of the cannula. The distal end of the needle includes a sharp tip producing a localized bright spot, under an ultrasound guidance, which is distinguishable from the bright and dark regions created via the echogenic pattern of the cannula.

The utility model discloses a percutaneous bile duct puncture channel plugging device, and relates to the technical field of medical instruments. The device comprises a puncture tube, a sheath tube is arranged in the puncture tube, an air bag is arranged in the sheath tube, and a protective layer is arranged on the surface of the air bag. The blocking assembly is arranged on the surface of the puncture tube, and the blocking assembly comprises a supporting tube. By arranging the air bag, the air bag can be moved into the puncture channel through the puncture tube after puncture treatment is finished, the air bag is communicated with external inflation equipment through the air inlet tube, and the air bag can be inflated and expanded to support a protective layer compressed gelatin sponge for plugging and enable the gelatin sponge to be attached to the tube wall, so that the rapid plugging effect is achieved; through the arrangement of the blocking assembly, blocking and shielding can be conducted on the external wound position of a patient through the first blocking pad and the second blocking pad in the puncture treatment process, bacteria are prevented from entering, and the protection effect is achieved.

The invention provides a bifunctional molecule compound for inducing degradation of MMP-7 protein or pharmaceutically acceptable salt, hydrate or prodrug thereof. The structure of the compound is as shown in formula I or II: # imgabs0 # formula I; and the # imgabs 1 # is shown as a formula II. The invention also provides a preparation method of the compound and a pharmaceutical composition. In addition, the invention also provides application of the compound, the pharmaceutically acceptable salt, the hydrate, the prodrug or the pharmaceutical composition thereof in preparation of drugs for treating biliary atresia. According to the invention, a PROTAC technology is used as a support, an MMP-7 inhibitor is used as a raw material, and a bifunctional molecular compound with different Linker lengths for inducing degradation of MMP-7 protein is synthesized; by using the bifunctional molecular compound after the biliary atresia, the effective degradation of the MMP-7 protein can be realized, the inflammatory bile duct injury and hepatic fibrosis progress can be inhibited, and a new treatment strategy is provided for the biliary atresia.

The utility model provides a laparoscope bile duct calculus taking-out device, and relates to the technical field of medical instruments, the laparoscope bile duct calculus taking-out device comprises an operating handle, one end of the operating handle is connected with a duodenoscope, a mechanism used for fixing the duodenoscope is arranged in the operating handle, the surface of the duodenoscope is fixedly sleeved with a shifting piece, and the shifting piece is connected with the operating handle. And a biliary tract sub-mirror is arranged in the duodenoscope. According to the device, the operation steps are very simple and convenient, the phenomenon that the duodenoscope possibly falls off after being used for a long time is avoided, the connecting efficiency of the duodenoscope and the operation handle is indirectly improved, and the practicability is greatly improved through the design.

The invention provides a biliary-intestinal anastomosis stent and a control method, the biliary-intestinal anastomosis stent comprises a tube body of an I-shaped structure on the whole, the tube body comprises a middle connecting tube, two liver branch tubes connected and communicated with the upper end of the middle connecting tube, and at least two intestinal branch tubes connected and communicated with the lower end of the middle connecting tube; the two hepatic branch canals are respectively placed into left and right hepatic canals of a patient; the middle connecting pipe is used for being inserted into a bile duct of a patient, and an anti-backflow structure used for preventing jejunum contents from flowing back is arranged in the middle connecting pipe; the at least two intestinal branch tubes are used for being placed in a jejunum chamber of a patient. The unique I-shaped design is adopted, the Y-shaped structure of the upper branch tube can be perfectly matched with anatomical forms of left and right hepatic ducts, symmetrical and stable supporting is achieved, and the situation that an anastomotic stoma is twisted or narrow due to uneven supporting of a traditional single tube is effectively avoided; and the Y-shaped structure of the lower branch pipe is opened in the enteric cavity, so that the stability of the stent is improved, and displacement is prevented.

Disclosed herein are improved pluripotent stem cell-derived biliary organoids, having extrahepatic cholangiocytes. In various embodiments, the biliary organoids can additionally include intrahepatic cholangiocytes. Also disclosed are methods of producing the biliary organoids having extrahepatic cholangiocytes. The disclosure also relates to methods of studying or treating a biliary-related disease or disorder using the described biliary organoids, including surgical methods such as in transplants, engraftments, ligations, and / or bililary bypass. The disclosure also includes surgical implants for biliary bypass. The disclosure additional describes methods of producing tubular organoids and cell culture devices for performing said methods.

The medical system includes a basket treatment tool a processor. The processor determines, one or more of: a first determination, based on a transmissive image including the biliary duct, of whether a size of a gallstone allows the basket treatment tool to remove the gallstone from the papillary orifice, or a second determination, based on a resistance when the basket treatment tool is pulled, of whether the resistance allows the basket treatment tool to remove the gallstone from the papillary orifice; and controls the basket treatment tool to remove the gallstone from the papillary orifice when one or more of the first determination or the second determination determines that the gallstone is removable from the papillary orifice.